Loading
A phase 2 trial of TGRX-326 in non-small-cell lung cancer and small-cell lung cancer, run by Shenzhen TargetRx Co., Ltd., active and no longer recruiting.
TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT05955391 by Shenzhen TargetRx Co., Ltd., with 164 participants enrolled, started 2023-01-18 and due to reach its primary completion in 2024-12-29. Interventions recorded: TGRX-326. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares TGRX-326, Shenzhen TargetRx, ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer.
Shares ALK-positive non-small-cell lung cancer, Small-cell lung cancer, Non-small-cell lung cancer.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer.
Shares ALK-positive non-small-cell lung cancer, Small-cell lung cancer, Non-small-cell lung cancer.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/